nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.02.2012 | Original Paper

Downregulation of EphA2 expression suppresses the growth and metastasis in squamous-cell carcinoma of the head and neck in vitro and in vivo

verfasst von: Yong Liu, Changyun Yu, Yuanzheng Qiu, Donghai Huang, Xiaojuan Zhou, Xin Zhang, Yongquan Tian

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Our previous study has revealed that EphA2 overexpression is significantly associated with aggressive behavior and poor prognosis in patients with squamous-cell carcinoma of the head and neck (SCCHN). However, the function of EphA2 in tumorigenesis and cervical lymph node metastasis of SCCHN has never been elucidated in vivo.

Methods

EphA2 was knocked down in SCCHN cell lines. CCK-8 assays, fluorescence-activated cell sorting analysis, invasion and migration assays were performed in vitro. In vivo tumorigenicity assays were performed, and the impact on cervical lymph node metastasis was evaluated.

Results

The present investigation demonstrated that suppression of EphA2 resulted in a significant inhibition of proliferation, migration, invasion of SCCHN cells in vitro and markedly diminished their tumorigenicity and lymph node metastasis in vivo.

Conclusions

These results suggest that EphA2 plays a critical role in SCCHN growth and metastasis and may be a promising therapeutic target to prevent the progression of SCCHN.

Bogan C, Chen J, O’Sullivan MG et al (2009) Loss of EphA2 receptor tyrosine kinase reduces ApcMin/+ tumorigenesis. Int J Cancer 124:1366–1371PubMedCrossRef

Brannan JM, Dong W, Prudkin L et al (2009a) Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 15:4423–4430PubMedCrossRef

Brannan JM, Sen B, Saigal B et al (2009b) EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila) 2:1039–1049CrossRef

Brantley-Sieders DM, Zhuang G, Hicks D et al (2008) The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118:64–78PubMedCrossRef

Carles-Kinch K, Kilpatrick KE, Stewart JC et al (2002) Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 62:2840–2847PubMed

Duxbury MS, Ito H, Zinner MJ et al (2004) EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 23:1448–1456PubMedCrossRef

Han L, Dong Z, Qiao Y et al (2005) The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol 99:278–286PubMedCrossRef

Herath NI, Spanevello MD, Sabesan S et al (2006) Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer 6:144PubMedCrossRef

Ireton RC, Chen J (2005) EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 5:149–157PubMedCrossRef

Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRef

Kinch MS, Moore MB, Harpole DH Jr (2003) Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9:613–618PubMed

Koolpe M, Dail M, Pasquale EB (2002) An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem 277:46974–46979PubMedCrossRef

Landen CN Jr, Chavez-Reyes A, Bucana C et al (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65:6910–6918PubMedCrossRef

Landen CN Jr, Lu C, Han LY et al (2006) Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 98:1558–1570PubMedCrossRef

Lin YG, Han LY, Kamat AA et al (2007) EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 109:332–340PubMedCrossRef

Liu Y, Xie C, Zhang X et al (2010) Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer 46:3007–3015PubMedCrossRef

Liu Y, Zhang X, Qiu Y et al (2011) Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck. J Cancer Res Clin Oncol 137:761–769PubMedCrossRef

Lu C, Shahzad MM, Wang H et al (2008) EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 7:1098–1103PubMedCrossRef

Mamelle G (2000) Selective neck dissection and sentinel node biopsy in head and neck squamous cell carcinomas. Recent Results Cancer Res 157:193–200PubMedCrossRef

Mamelle G, Pampurik J, Luboinski B et al (1994) Lymph node prognostic factors in head and neck squamous cell carcinomas. Am J Surg 168:494–498PubMedCrossRef

Margaryan NV, Strizzi L, Abbott DE et al (2009) EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther 8:279–288PubMedCrossRef

Meade-Tollin L, Martinez JD (2007) Loss of p53 and overexpression of EphA2 predict poor prognosis for ovarian cancer patients. Cancer Biol Ther 6:288–289PubMedCrossRef

Pasquale EB (1997) The Eph family of receptors. Curr Opin Cell Biol 9:608–615PubMedCrossRef

Pasquale EB (2005) Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 6:462–475PubMedCrossRef

Pasquale EB (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133:38–52PubMedCrossRef

Rivera RS, Gunduz M, Nagatsuka H et al (2008) Involvement of EphA2 in head and neck squamous cell carcinoma: mRNA expression, loss of heterozygosity and immunohistochemical studies. Oncol Rep 19:1079–1084PubMed

Shao Z, Zhang WF, Chen XM et al (2008) Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome. Oral Oncol 44:1110–1117PubMedCrossRef

Sulman EP, Tang XX, Allen C et al (1997) ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics 40:371–374PubMedCrossRef

Thaker PH, Deavers M, Celestino J et al (2004) EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10:5145–5150PubMedCrossRef

Walker-Daniels J, Coffman K, Azimi M et al (1999) Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 41:275–280PubMedCrossRef

Wu Z, Doondeea JB, Moghaddas Gholami A et al. (2011) Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol Cell Proteomics [Epub ahead of print]

Wykosky J, Gibo DM, Stanton C et al (2005) EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 3:541–551PubMedCrossRef

Zantek ND, Azimi M, Fedor-Chaiken M et al (1999) E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 10:629–638PubMed

Zelinski DP, Zantek ND, Stewart JC et al (2001) EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61:2301–2306PubMed

Zhang X, Liu Y, Gilcrease MZ et al (2002) A lymph node metastatic mouse model reveals alterations of metastasis-related gene expression in metastatic human oral carcinoma sublines selected from a poorly metastatic parental cell line. Cancer 95:1663–1672PubMedCrossRef

Zhang X, Su L, Pirani AA et al (2006) Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis. Clin Exp Metastasis 23:209–222PubMedCrossRef

Zhou Z, Yuan X, Li Z et al (2008) RNA interference targeting EphA2 inhibits proliferation, induces apoptosis, and cooperates with cytotoxic drugs in human glioma cells. Surg Neurol 70:562–568 (discussion 568–569)PubMedCrossRef

Titel: Downregulation of EphA2 expression suppresses the growth and metastasis in squamous-cell carcinoma of the head and neck in vitro and in vivo
verfasst von: Yong Liu
Changyun Yu
Yuanzheng Qiu
Donghai Huang
Xiaojuan Zhou
Xin Zhang
Yongquan Tian
Publikationsdatum: 01.02.2012
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2012
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-011-1087-9

Springer Medizin

Downregulation of EphA2 expression suppresses the growth and metastasis in squamous-cell carcinoma of the head and neck in vitro and in vivo

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Growth pattern of renal cell carcinoma (RCC) in patients with delayed surgical intervention

Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt’s lymphoma cells

Histopathology of surgically treated renal tumours in young adults: a developing country perspective

The role of leptin receptor gene polymorphisms in determining the susceptibility and prognosis of NSCLC in Chinese patients

Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity

PAX3/7–FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie